Clinical Trial: Alzheimer's Disease and Aging: Therapeutic potential of estrogen


	Home	\|	Search	\|	Browse	\|	Resources	\|	Help	\|	What's New	\|	About

Alzheimer's Disease and Aging: Therapeutic potential of estrogen

This study is currently recruiting patients.

Sponsored by:	Department of Veterans Affairs
Information provided by:	Department of Veterans Affairs

Purpose

This study is designed to evaluate the potential beneficial effects of estrogen on cognitive function of women with Alzheimer's Disease.

Condition	Treatment or Intervention	Phase
Alzheimer's Disease	Drug: estrogen	Phase II

Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study

Further Study Details:

Study start: April 1998; Expected completion: March 2001

Eligibility

Ages Eligible for Study: 50 Years - 90 Years, Genders Eligible for Study: Female

Criteria

Post menopausal women with alzheimer's disease
free of any major medical or neurological disease,
medically safe to be treated with estrogen.

Location and Contact Information

Washington
VA Puget Sound Health Care System, Lakewood, Washington, 98493-5000, United States; Recruiting

Sanjay Asthama, MD 253-582-8440 Ext. 6925 sasthana@u.washington.edu
Sanjay Asthana, Principal Investigator

Study chairs or principal investigators

Suzanne Craft, Ph.D
Laura Baker, Ph.D
Murray Raskind, M.D.

More Information

Study ID Numbers: AGCG-007-97F
Record last reviewed: June 2001
Record first received: July 3, 2001
ClinicalTrials.gov Identifier: NCT00018343
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2004-11-16

U.S. National Library of Medicine, Contact NLM Customer Service

National Institutes of Health, Department of Health & Human Services